Antibody Engineering2021-10-20T06:46:33-04:00

Antibody Engineering.

Minimize immunogenicity.

Advancements in protein sequencing technologies make it possible to work off of the exact amino acid sequence of any antibody species, allowing easy modification. This knowledge both enables and simplifies grafting any host regions of interest onto a desired backbone.

Next generation protein sequencing (NGPS) continues to facilitate recombinant expression to ease manipulation and engineering. More importantly, when modifications, mispairings, or mutations occur through time, proteomics can also help confirm the protein sequence in every step throughout the therapeutic pipeline.

Research teams are using NGPS for therapeutic and diagnotic projects focused on humanization and/or chimerization of antibodies, development of nanobodies, scvFs, and/or engineering of bi/tri/multi-specific antibodies.

Whitepaper: Prevalence of Secondary Light Chains

Services for antibody engineering.

We support the antibody engineering efforts of life science companies in all stages of development. Contact Us to discover how we can help with your antibody engineering application.

de novo mAb Sequencing

Obtain the sequence of an important antibody to facilitate protein characterization and future engineering. Obtain CDR sequences to add to your framework or platform.
Explore REmAb

Recombinant Expression

Recombinantly express your engineered mAb. Choose HEK or CHO, talk to experts about transient expression and antibody production.
Explore REmAb + Expression

Quality Control and Troubleshooting

Routinely confirm that your produced antibody matches the expected or engineered sequence. Save time troubleshooting functional issues.
Explore MATCHmAb

Application Publications.

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

Tags: , , , , , , , , , , |

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

What are Monoclonal Antibodies?

Tags: , , , , , , , , |

Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences

Talk to Our Scientists.

We Have Sequenced 4000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 3000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 4000 antibodies and we are eager to help you.